INT255120

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.62
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 29
Total Number 49
Disease Relevance 10.82
Pain Relevance 0.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mRNA binding (Celf1) mRNA processing (Celf1) RNA binding (Celf1)
nucleus (Celf1) cytoplasm (Celf1)
Anatomy Link Frequency
heart 5
myoblasts 4
muscle cells 2
muscle 2
skeletal muscle 2
Celf1 (Mus musculus)
Pain Link Frequency Relevance Heat
anesthesia 39 95.60 Very High Very High Very High
GABAergic 30 94.32 High High
Kinase C 14 91.80 High High
Inflammation 21 82.20 Quite High
cytokine 42 61.72 Quite High
tolerance 61 5.00 Very Low Very Low Very Low
Central nervous system 42 5.00 Very Low Very Low Very Low
imagery 30 5.00 Very Low Very Low Very Low
gABA 27 5.00 Very Low Very Low Very Low
spastic colon 21 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Targeted Disruption 839 100.00 Very High Very High Very High
Myotonic Dystrophy 518 99.72 Very High Very High Very High
Congenital Anomalies 393 99.20 Very High Very High Very High
Disease 451 95.88 Very High Very High Very High
Death 36 95.20 Very High Very High Very High
Arrhythmias 2 Under Development 193 94.92 High High
Cv General 2 Under Development 72 94.20 High High
Insulin Resistance 63 93.04 High High
Frailty 285 92.12 High High
Arrhythmia Under Development 74 90.40 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CUGBP1 transgenic mice with the levels of CUGBP1 matching those in CDM patients (approximately 5-fold) showed a delay in development and died in utero or shortly after birth [73].
Gene_expression (levels) of CUGBP1 associated with myotonic dystrophy and targeted disruption
1) Confidence 0.62 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.53 Pain Relevance 0
However, transgenic mice overexpressing CUGBP1 developed splicing abnormalities suggesting that misregulation of splicing of CUGBP1 targets in vivo is independent of MBNL1 [68].
Gene_expression (overexpressing) of CUGBP1 associated with targeted disruption and congenital anomalies
2) Confidence 0.62 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.29 Pain Relevance 0
Two reports addressing total cellular levels of CUGBP1 in DM2 cells did not find differences in CUGBP1 levels [66,67].
Gene_expression (levels) of CUGBP1
3) Confidence 0.62 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.21 Pain Relevance 0
The elevation of CUGBP1 has been also reported for DM2 patients [52]; however, there are contradictory results for expression of CUGBP1 in DM2.
Gene_expression (expression) of CUGBP1
4) Confidence 0.62 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.22 Pain Relevance 0
Given these additional activities of CUGBP1, it is not surprising that lower or high levels of expression of CUGBP1 have a toxic effect on normal development [73,89].
Gene_expression (expression) of CUGBP1
5) Confidence 0.62 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.54 Pain Relevance 0.07
CUGBP1 is expressed in both nucleus and cytoplasm.
Gene_expression (expressed) of CUGBP1 in nucleus
6) Confidence 0.62 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0 Pain Relevance 0
Molecular analysis of the “inducible” transgenic mice with overt DM1 phenotype showed that these mice have increased levels of CUGBP1 (CUG-binding protein 1) [34].
Gene_expression (levels) of CUG-binding protein 1 associated with targeted disruption
7) Confidence 0.62 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.50 Pain Relevance 0
Molecular analysis of the “inducible” transgenic mice with overt DM1 phenotype showed that these mice have increased levels of CUGBP1 (CUG-binding protein 1) [34].
Gene_expression (levels) of CUGBP1 associated with targeted disruption
8) Confidence 0.62 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.50 Pain Relevance 0
Comprehensive analysis of CUGBP1 in DM2 cells and in DM2 models revealed several essential differences in CUGBP1 function in DM2 compared to DM1.
Gene_expression (function) of CUGBP1
9) Confidence 0.54 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.07 Pain Relevance 0
Early elevation of CUGBP1 in transgenic mice expressing CUG repeats shows that the increase of CUGBP1 is not a consequence of different abnormalities in DM1 but rather a direct result of expression of the mutant CUG repeats [64].
Gene_expression (expressing) of CUGBP1 associated with targeted disruption and congenital anomalies
10) Confidence 0.54 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.29 Pain Relevance 0
CUGBP1 transgenic mice with the levels of CUGBP1 matching those in CDM patients (approximately 5-fold) showed a delay in development and died in utero or shortly after birth [73].
Gene_expression (levels) of CUGBP1 associated with myotonic dystrophy and targeted disruption
11) Confidence 0.54 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.53 Pain Relevance 0
Elevation of CUGBP1 in DM2 muscle cells and tissues suggests that CUGBP1-dependent pathways might be also altered in DM2 cells similar to alterations observed in DM1.
Gene_expression (muscle cells) of CUGBP1 in muscle cells
12) Confidence 0.54 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.08 Pain Relevance 0
Analysis of CUGBP1 stability in DM2 myoblasts and in normal cells expressing CCUG repeats showed that the stability of CUGBP1 is also increased in the presence of CCUG repeats [52].
Gene_expression (stability) of CUGBP1 in myoblasts
13) Confidence 0.54 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.05 Pain Relevance 0
CUGBP1 transgenic mice with the levels of CUGBP1 matching those in CDM patients (approximately 5-fold) showed a delay in development and died in utero or shortly after birth [73].
Gene_expression (transgenic mice) of CUGBP1 associated with myotonic dystrophy and targeted disruption
14) Confidence 0.54 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.53 Pain Relevance 0
Elevation of CUGBP1 in DM2 muscle cells and tissues suggests that CUGBP1-dependent pathways might be also altered in DM2 cells similar to alterations observed in DM1.
Gene_expression (Elevation) of CUGBP1 in muscle cells
15) Confidence 0.54 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.08 Pain Relevance 0
Growing number of new reports suggest that additional pathways are involved in the regulation of activity and levels of CUGBP1 in DM1 and DM2 cells.
Gene_expression (levels) of CUGBP1
16) Confidence 0.54 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.06 Pain Relevance 0
Given these additional activities of CUGBP1, it is not surprising that lower or high levels of expression of CUGBP1 have a toxic effect on normal development [73,89].
Gene_expression (expression) of CUGBP1
17) Confidence 0.54 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.55 Pain Relevance 0.07
Immunoprecipitation of CUGBP1 from normal and DM1 cultured cells also showed strong interaction of CUGBP1 with the mutant DMPK mRNA in DM1 cells but not in normal cells [40].
Gene_expression (Immunoprecipitation) of CUGBP1
18) Confidence 0.54 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.10 Pain Relevance 0
Since CUGBP1 has been not found in the nuclear CUG and CCUG aggregates, nuclear CUG and CCUG foci do not appear to affect CUGBP1 levels.
Gene_expression (levels) of CUGBP1
19) Confidence 0.54 Published 2010 Journal Current Genomics Section Body Doc Link PMC2874224 Disease Relevance 0.12 Pain Relevance 0
The expanded CUGn and CCUGn RNAs mainly target two RNA binding proteins, MBNL1 and CUGBP1, elevating levels of CUGBP1 and reducing levels of MBNL1.
Gene_expression (levels) of CUGBP1
20) Confidence 0.48 Published 2010 Journal Current Genomics Section Abstract Doc Link PMC2874224 Disease Relevance 0.59 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox